Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. The company has a strategic collaboration with SCT Cell Manufacturing s.r.o. to streamline development, accelerate timelines and bring advanced therapies to patients faster. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina. Show more

Location: 8 Moore Drive, Durham, NC, 27709, United States | Website: https://www.fortrea.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.316B

52 Wk Range

$3.97 - $23.21

Previous Close

$14.24

Open

$14.50

Volume

615,162

Day Range

$14.06 - $14.64

Enterprise Value

2.372B

Cash

131.3M

Avg Qtr Burn

N/A

Insider Ownership

0.56%

Institutional Own.

-

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date